Loading
Usana Health Sciences Inc Stock: price and insider trades · United States
Usana Health Sciences Inc: what insiders have been doing
Usana Health Sciences Inc, founded in 1992, is a Healthcare & Pharma company based in Salt Lake City, United States. Its directors and officers file their transactions with SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Usana Health Sciences Inc logged 65 filings by 18 insiders.
Only sales appear on the open market, 9 sales in all totalling €357k, filed by 6 insiders. At €81k, the sale published on 23 February 2026 by Foukas Joshua is the largest of the period.
For context, the typical company on the same exchange (median of 5,813 companies) published 19 filings over the same period, against 65 filings here. Looking back to 2016, when coverage begins, insiders filed no purchases and 106 sales. The 10-K for the year ended 3 January 2026 shows 925.3 m USD of revenue and 10.8 m USD of net income.
The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
400
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€11M
106 ops. · all time
Who traded when
BuySaleGilbert A. Fuller4 sales
John Turman Fleming4 sales
Mulham David Mulham3 sales
Foukas Joshua2 sales
Peter Benedict2 sales
Brown Jim1 sale
+5 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Usana Health Sciences Inc Strong Buy (bullish), based on 1 analysts. Average price target: US$25.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,429 of 24,148 companies
63.2
score / 100
Value70
Quality57
FCF yld3.0%
Earn yld3.8%
EV/EBITDA3.7x
ROE-5.1%
Gross mgn78%
Net mgn1.2%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$15.38
Analyst consensus
1 analystsStrong buy
US$25.00Target US$25.00(+63%)US$25.00
Income statement
RevenueUS$925.3M
Gross profitUS$724.4M78% margin
EBITDAUS$82.1M9% margin
Net incomeUS$10.8M-2.4% margin
Valuation
PER (trailing)28.7x
PER (forward)8.7x
P/Book0.5x
Beta0.68
Balance sheet & cash
Market capUS$284.2M
Total debtUS$19.7M
Free Cash FlowUS$8.5M
Debt / Equity2%
Profitability & ownership
ROE-5.1%
ROA3.6%
% insiders40.9%
% institutions62.8%
Last declaration on 27 July 2026
Declarations400 total
1,632 sharesCommon StockSEC:0001709352-26-000008:0
1,632 sharesCommon StockSEC:0001763161-26-000011:0
1,632 sharesCommon StockSEC:0001261778-26-000007:0
1,632 sharesCommon StockSEC:0001673356-26-000008:0
1,166 sharesCommon StockSEC:0002053876-26-000006:0
598 sharesCommon StockSEC:0002032126-26-000010:0
1,632 sharesCommon StockSEC:0001203302-26-000012:0
1,632 sharesCommon StockSEC:0001824992-26-000008:0
518 shares@ US$21.320.0042% mcap100.0% of flowCommon StockSEC:0002053876-26-000006:1
176 shares@ US$21.320.0014% mcap2.6% of flowCommon StockSEC:0002032126-26-000010:1
935 shares@ US$20.920.0074% mcap24.3% of flowCommon StockSEC:0001763161-26-000011:1
408 shares@ US$20.920.0032% mcap63.2% of flowCommon StockSEC:0001261778-26-000007:1
5,002 shares@ US$19.453184.2% of flowCommonSEC144:0001950047-26-006236
909 shares@ US$20.005315.8% of flowCommonSEC144:0001950047-26-006159
5,561 shares@ US$18.50100.0% of flowCommonSEC144:0001950047-26-005769
2,450 shares@ US$17.930.018% mcap14.2% of flowCommon StockSEC:0001824992-26-000006:0
264 shares@ US$19.240.0021% mcap36.8% of flowCommon StockSEC:0001261778-26-000003:1
668 shares@ US$19.240.0052% mcap15.6% of flowCommon StockSEC:0001763161-26-000006:1
1,057 sharesCommon StockSEC:0001203302-26-000006:0
1,057 sharesCommon StockSEC:0001824992-26-000002:0
1,057 sharesCommon StockSEC:0001709352-26-000004:0
25 of 400 declarations
About Usana Health Sciences Inc
USANA Health Sciences, Inc. (NYSE: USNA) is a U.S.-based health and wellness company headquartered in Salt Lake City, Utah, United States. Founded in 1992 by Myron W. Wentz, Ph.D., the company develops and manufactures nutritional supplements, functional foods, personal care items, and skincare products, with a long-standing emphasis on science-based preventive health. Historically, USANA built its business through direct selling, using Brand Partners and Preferred Customers as the core of its commercial engine. More recently, the company has broadened its go-to-market mix and now operates across an omni-channel platform that also includes direct-to-consumer, third-party marketplace, and retail channels.
USANA reports two business segments: its core nutritional business and Hiya, its direct-to-consumer children’s health platform. The Hiya acquisition, completed in December 2024 with a 78.85% ownership interest, meaningfully expanded USANA’s exposure to the DTC channel and added a differentiated growth layer outside the legacy direct-selling structure. The company also acquired Rise in 2022 and has continued to expand that brand’s product range and distribution footprint over the past three years. Together, these moves indicate a broader strategic effort to diversify revenue sources while leveraging the company’s established nutrition and wellness capabilities.
Read moreShow less
From a competitive standpoint, USANA positions itself around “cellular nutrition,” premium-quality products, and a science-led brand identity. Its international footprint remains an important differentiator: the company operates in 25 geographic markets worldwide, giving it scale and brand reach, while also increasing exposure to foreign exchange volatility and local regulatory complexity. Mainland China is USANA’s largest market and its single largest source of revenue, accounting for about 41.3% of net sales and nearly half of core nutritional active customers in the latest annual report. That concentration creates both opportunity and risk for investors.
USANA’s key product lines include Nutritionals and Celavive skincare, alongside products such as CellSentials, BiOmega, HealthPak and Proflavanol. In 2025, the company announced a substantial refresh of its portfolio, including new product launches, reformulations, and upgraded packaging. It also introduced a Health Professional Advisory Council to support product development and credibility in the wellness space. Management has highlighted the new launches and the integration of Hiya as part of a broader growth strategy.
Financially, USANA generated approximately $925 million in net sales in fiscal 2025. For investors, the story is one of a mature international health-and-wellness platform that is trying to evolve beyond its historical direct-selling model. The company’s listing on the NYSE in the United States gives it visibility among U.S.-listed consumer health names, but execution risk remains tied to channel transition, product innovation, China exposure, and currency movements.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
